Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Author:
Affiliation:
1. Academic Medical Centre; Internal Medicine; Meibergdreef 9 Amsterdam Netherlands 1105 AZ
Publisher
Wiley
Subject
Pharmacology (medical)
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006383.pub2/fullpdf
Reference42 articles.
1. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes;Hollander;Clinical Therapeutics,2008
2. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes;Raskin;Diabetes Metabolism Research and Reviews,2009
3. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes;Rosenstock;Diabetologia,2008
4. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs;Swinnen;Diabetes Care,2010
5. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: A double-blind, randomized, crossover study;King;Diabetes, Obesity and Metabolism,2009
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Association between glucose-lowering drugs and circulating insulin antibodies induced by insulin therapy in patients with type 2 diabetes;World Journal of Diabetes;2024-07-15
2. Current Assays in Endocrine Safety Pharmacology;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2024
3. Injectable systems for long-lasting insulin therapy;Advanced Drug Delivery Reviews;2023-12
4. Enhancing Stability and Albumin Binding Efficiency of α-Conotoxin GI through Fatty Acid Modification;Biochemistry;2023-11-15
5. Pharmacotherapy of type 2 diabetes: An update and future directions;Metabolism;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3